A recent study published in The Lancet has revealed that Ozempic, known generically as semaglutide, can aid individuals with type 2 diabetes suffering from peripheral artery disease (PAD). This circulatory condition restricts blood flow to the limbs, often due to plaque buildup in arteries. Findings indicated that a 1 mg dosage resulted in a 13% increase in walking distance over a placebo, alongside improved ankle-brachial indices, a crucial measure of lower limb blood flow.
The research highlights semaglutide’s multiple health benefits beyond just managing blood sugar and facilitating weight loss. Prior studies have shown its potential to reduce cardiovascular risks, enhance kidney health, and mitigate certain addiction behaviours. These multifaceted advantages make it a noteworthy player in diabetes management.
Peripheral artery disease is marked by severely narrowed arteries that decrease blood flow to arms and legs, leading to pain and disability. With over 230 million individuals affected globally, effective treatments to prevent complications for diabetics are still lacking. Despite the dire implications, innovative therapies, like semaglutide, offer newfound hope.
Dr. Subodh Verma, a leading researcher on the study, emphasised that PAD significantly hampers mobility, often going unrecognised in its initial stages. The trial’s results are promising; patients exhibited increased walking distance over 26 weeks, extending to 52 weeks without a plateau, indicating semaglutide’s potential for long-term usage.
The fear of amputation, a dire consequence of PAD, looms especially large for diabetic patients, who are 10-20 times more likely to face this reality compared to their non-diabetic counterparts. In light of these findings, Novo Nordisk has initiated a label extension application for Ozempic with the US FDA, paving the way for expanded use in treatment.
Ozempic, or semaglutide, has shown promising results for diabetes patients with peripheral artery disease, enhancing their walking distances by 13% and improving blood flow as indicated by ankle-brachial indices. This research highlights its multiple health benefits beyond blood sugar regulation. The study indicates potential for long-term usage, with Novo Nordisk pursuing FDA label extensions for Ozempic.
In summary, Ozempic (semaglutide) emerges as a beacon of hope for those grappling with diabetes-related peripheral artery disease. This study sheds light on its ability to enhance walking ability and improve overall health outcomes. With its potential for long-term therapy, it significantly alters the landscape of diabetes treatment and may reduce the fear of severe complications such as amputation.
Original Source: indianexpress.com
